1-855-RxRxCSS / 1-855-797-9277

About Us

The Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, Mariposa, is a new cancer center that offers state-of-the-art diagnosis, treatment, and access to clinical trials, with a dedicated team of experienced medical professionals who are committed to providing personalized care.

What We Do:

We make molecularly-informed decisions. Our highly-specific tissue & serum diagnostics enable precision therapy based on the unique molecular signature of the tumor across time and space to achieve the optimal therapeutic outcome. Throughout the course of treatment at Chan Soon-Shiong Institute for Medicine at Mariposa, comprehensive genomic, transcriptomic, and proteomic profiling of the patient’s tumor and blood will be used to understand spatiotemporal tumor evolution and direct treatment.

We champion the administration of low-dose chemotherapy and radiotherapy combined with immunotherapy to preserve and retrain the patient’s immune system against their cancer. Growing evidence suggests that transformed cancer cells occur routinely as part of the physiological process of regeneration. In healthy persons, a steady state exists between an Equilibrium phase and Elimination phase, where the natural immune response eliminates malignant cells. When this steady state is overwhelmed by mutations or by the immunosuppressive nature of the tumor microenvironment, the Escape phase ensues, with resultant tumor development, evolution and clinical manifestation. A paradigm shift in cancer care is necessary to overcome the immunogenic disequilibrium of the escape phase.evolution and direct treatment.

CSSIFM-office
CSSIFM-office
CSSIFM-office
CSSIFM-office
CSSIFM-office
CSSIFM-office
CSSIFM-office
conference room
Infusion Center
Arrow
Arrow
ArrowArrow
Slider

For More Information

1-855-RxRxCSS

1-855-797-9277

Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, Mariposa
2040 East Mariposa Avenue
El Segundo, California 90245

We are not currently accepting walk-ins. Please call to schedule an appointment.

Meet the Team

John-H-Lee-M.D-F.A.C.SJohn Lee, MD FACS
Co-Director

John Lee grew up on a small dairy farm in Northern Minnesota. He did his undergraduate education at Stanford University graduating with a B.S. with honors in biology. He received his M.D. degree from the University of Minnesota. Dr. Lee completed residency and fellowship training in Head and Neck Surgery at the University of Iowa.

He stayed on staff and was promoted to associate professor. During time from undergraduate throughout his career he has focused not only on medical training but also translational research.

In 2008, Dr. Lee took a position to build a head and neck cancer program at Sanford Health. While there as the physician lead for the system he developed a large head and neck program that focuses on bringing immune oncology drugs to patients. Academically, he was promoted to full professor and also was promoted to medical director of oncology research. He initiated and chaired the systems protocol review committee for all incoming oncology trials and developed several initiated trials within Sanford.

In addition, his lab produced over 40 peer-reviewed papers, multiple patents and maintained continuous NIH funding. Dr. Lee has a passion is to improve long term cures and reduce morbidity of oncology treatments using the bodies’ immune response.

In 2016, Dr. Lee moved to Southern California to assume the positions of Senior Vice President of Adult Medical Affairs at NantKwest and Co-Director of the Chan Soon-Shiong Institute for Medicine at Mariposa. For enjoyment Dr. Lee enjoys the outdoors, especially hunting and fishing.

John Lee grew up on a small dairy farm in Northern Minnesota. He did his undergraduate education at Stanford University graduating with a B.S. with honors in biology. He received his M.D. degree from the University of Minnesota. Dr. Lee completed residency and fellowship training in Head and Neck Surgery at the University of Iowa.

He stayed on staff and was promoted to associate professor. During time from undergraduate throughout his career he has focused not only on medical training but also translational research. In 2008, Dr. Lee took a position to build a head and neck cancer program at Sanford Health. While there as the physician lead for the system he developed a large head and neck program that focuses on bringing immune oncology drugs to patients. Academically, he was promoted to full professor and also was promoted to medical director of oncology research. He initiated and chaired the systems protocol review committee for all incoming oncology trials and developed several initiated trials within Sanford.

In addition, his lab produced over 40 peer-reviewed papers, multiple patents and maintained continuous NIH funding. Dr. Lee has a passion is to improve long term cures and reduce morbidity of oncology treatments using the bodies’ immune response.

In 2016, Dr. Lee moved to Southern California to assume the positions of Senior Vice President of Adult Medical Affairs at NantKwest and Co-Director of the Chan Soon-Shiong Institute for Medicine at Mariposa. For enjoyment Dr. Lee enjoys the outdoors, especially hunting and fishing.


Sandeep Reddy, MDSandeep Reddy, MD

Dr. Reddy received his M.D. from the Geffen School of Medicine at the University of California, Los Angeles after receiving his B.S. in biomedical sciences from the University of California, Riverside. Dr. Reddy was Chief Medical Officer at Caris Life Sciences prior to joining the Chan Soon-Shiong Institute for Medicine at Mariposa. His executive and medical oversight produced over 100 abstracts at major medical conferences and over 30 peer-reviewed publications since 2014.

Previously, Dr. Reddy was Chief of Staff at Los Alamitos Medical Center and actively practicing clinical hematology and oncology.

Simultaneously he held an adjunct faculty position at the Geffen/UCLA School of Medicine as a clinical instructor at Harbor-UCLA Medical Center, where he was awarded the distinguished teaching award for clinical faculty in 2006. He is a member of the Los Angeles Biomedical Institute, ASCO, IASLC and current SWOG investigator. His medical training includes fellowship training in hematology and medical oncology and therapeutics research at the City of Hope, and Internal Medicine residency at Harbor-UCLA Medical Center.

Dr. Reddy received his M.D. from the Geffen School of Medicine at the University of California, Los Angeles after receiving his B.S. in biomedical sciences from the University of California, Riverside. Dr. Reddy was Chief Medical Officer at Caris Life Sciences prior to joining the Chan Soon-Shiong Institute for Medicine at Mariposa. His executive and medical oversight produced over 100 abstracts at major medical conferences and over 30 peer-reviewed publications since 2014.

Previously, Dr. Reddy was Chief of Staff at Los Alamitos Medical Center and actively practicing clinical hematology and oncology. Simultaneously he held an adjunct faculty position at the Geffen/UCLA School of Medicine as a clinical instructor at Harbor-UCLA Medical Center, where he was awarded the distinguished teaching award for clinical faculty in 2006. He is a member of the Los Angeles Biomedical Institute, ASCO, IASLC and current SWOG investigator. His medical training includes fellowship training in hematology and medical oncology and therapeutics research at the City of Hope, and Internal Medicine residency at Harbor-UCLA Medical Center.


Tara E. Seery, MDTara E. Seery, MD

Dr. Tara E. Seery is a medical oncologist who specializes in treating cancers of the pancreas, esophagus, colon, rectum, anus, and liver. She has extensive experience in pancreatic cancer, including multiple publications, and is one of the highest enrollers in an early phase pancreatic cancer trial.

Dr. Seery received her M.D. from University College Dublin School of Medicine after receiving her B.S. from Vanderbilt University. Dr. Seery did her residency and fellowship training in hematology/oncology at Caritas St. Elizabeth Medical Center in Boston and completed her fellowship training at the University of Illinois at Chicago.

Most recently, Dr. Seery was an Associate Professor at UC Irvine in the Division of Hematology Oncology where she received the prestigious C. Ronal Koons, M.D. Humanitarian Award for service and compassion to patients.

Compassion and hope have driven Dr. Seery toward specializing in gastro-intestinal cancers. Although no one in her family is in medicine, she has been passionate about becoming a physician since she was five years old. Dr. Seery states that “joining CSSIFM is exciting because we are offering patients more hope, a better quality of life, and our future is to cure cancer.” Her plan is to help lead the pancreatic cancer studies for CSSIFM.

She enjoys teaching and was recently featured at the Hematology/Oncology Fellowship Annual Lecture Series. Her research experience includes neoadjuvant chemotherapy and intraoperative chemotherapy for resectable pancreatic cancer and Corydalis Yanhusuo for prevention of chemotherapy induced neuropathy. She has been the primary investigator for 20 oncology trials. Dr. Seery has been published numerous times, has many abstracts, and is an invited speaker around the world.

Dr. Seery has lived in Southern California since 2010, enjoys running and spending time with her husband and young daughter.

Dr. Tara E. Seery is a medical oncologist who specializes in treating cancers of the pancreas, esophagus, colon, rectum, anus, and liver. She has extensive experience in pancreatic cancer, including multiple publications, and is one of the highest enrollers in an early phase pancreatic cancer trial.

Dr. Seery received her M.D. from University College Dublin School of Medicine after receiving her B.S. from Vanderbilt University. Dr. Seery did her residency and fellowship training in hematology/oncology at Caritas St. Elizabeth Medical Center in Boston and completed her fellowship training at the University of Illinois at Chicago.

Most recently, Dr. Seery was an Associate Professor at UC Irvine in the Division of Hematology Oncology where she received the prestigious C. Ronal Koons, M.D. Humanitarian Award for service and compassion to patients.

Compassion and hope have driven Dr. Seery toward specializing in gastro-intestinal cancers. Although no one in her family is in medicine, she has been passionate about becoming a physician since she was five years old. Dr. Seery states that “joining CSSIFM is exciting because we are offering patients more hope, a better quality of life, and our future is to cure cancer.” Her plan is to help lead the pancreatic cancer studies for CSSIFM.

She enjoys teaching and was recently featured at the Hematology/Oncology Fellowship Annual Lecture Series. Her research experience includes neoadjuvant chemotherapy and intraoperative chemotherapy for resectable pancreatic cancer and Corydalis Yanhusuo for prevention of chemotherapy induced neuropathy. She has been the primary investigator for 20 oncology trials. Dr. Seery has been published numerous times, has many abstracts, and is an invited speaker around the world.

Dr. Seery has lived in Southern California since 2010, enjoys running and spending time with her husband and young daughter.


Lennie Sender, MDLennie Sender, MD
Co-Director

Dr. Sender received his M.D. degree at the University of the Witwatersrand in Johannesburg, South Africa. He completed internship and residency in pediatrics at the University of California, Irvine and a fellowship in pediatric hematology-oncology at Children’s Hospital Los Angeles.

In his more than 20 years of experience treating pediatric, adolescent, and young adult cancer patients and survivors, he has seen how the field of oncology has changed and how concerted efforts are now made to address patients’ ancillary needs, including fertility preservation, management of acute and chronic treatment effects, and to be sensitive to the psychosocial impacts of a cancer diagnosis on those just beginning their most productive years.

Dr. Sender’s research interests are comprehensive and multidisciplinary, extending from epidemiological components (incidence, prevalence), to biological factors (genomic or cellular differences), to the psychosocial impact of cancer, to long-term cancer survivorship. In 2011, Dr. Sender was the recipient of a $10 million Hyundai Hope on Wheels grant to study the genomic basis of pediatric and adolescent and young adult cancers to test the hypothesis that genomic knowledge can enable clinical decisions related to treatment options. In 2010, he founded two entities critical to the development of the emerging adolescent and young adult (AYA) oncology subspecialty as President of the Society for Adolescent and Young Adult Oncology (SAYAO) and Editor-in-Chief of the Journal of Adolescent and Young Adult Oncology (JAYAO). Dr. Sender currently serves as the Medical Director of the Hyundai Cancer Institute at CHOC Children’s and has recently been named as the Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology for NantKwest.

Prior to joining NantKwest, Dr. Sender was the Medical Director of Clinical Oncology at the University of California’s NCI designated Chao Family Comprehensive Cancer Center. Dr. Sender also serves as Co-Director of the Chan Soon-Shiong Institute for Medicine at Mariposa.

Dr. Sender received his M.D. degree at the University of the Witwatersrand in Johannesburg, South Africa. He completed internship and residency in pediatrics at the University of California, Irvine and a fellowship in pediatric hematology-oncology at Children’s Hospital Los Angeles.

In his more than 20 years of experience treating pediatric, adolescent, and young adult cancer patients and survivors, he has seen how the field of oncology has changed and how concerted efforts are now made to address patients’ ancillary needs, including fertility preservation, management of acute and chronic treatment effects, and to be sensitive to the psychosocial impacts of a cancer diagnosis on those just beginning their most productive years. Dr. Sender’s research interests are comprehensive and multidisciplinary, extending from epidemiological components (incidence, prevalence), to biological factors (genomic or cellular differences), to the psychosocial impact of cancer, to long-term cancer survivorship. In 2011, Dr. Sender was the recipient of a $10 million Hyundai Hope on Wheels grant to study the genomic basis of pediatric and adolescent and young adult cancers to test the hypothesis that genomic knowledge can enable clinical decisions related to treatment options. In 2010, he founded two entities critical to the development of the emerging adolescent and young adult (AYA) oncology subspecialty as President of the Society for Adolescent and Young Adult Oncology (SAYAO) and Editor-in-Chief of the Journal of Adolescent and Young Adult Oncology (JAYAO). Dr. Sender currently serves as the Medical Director of the Hyundai Cancer Institute at CHOC Children’s and has recently been named as the Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology for NantKwest.

Prior to joining NantKwest, Dr. Sender was the Medical Director of Clinical Oncology at the University of California’s NCI designated Chao Family Comprehensive Cancer Center. Dr. Sender also serves as Co-Director of the Chan Soon-Shiong Institute for Medicine at Mariposa.


Patrick Soon-Shiong, MDPatrick Soon-Shiong
MBBCh, MSc, FRCS (C), FACS

Patrick Soon-Shiong, MD, a physician, surgeon, researcher, philanthropist and scientist, invented and developed the revolutionary drug Abraxane, which has received FDA approval for the treatment of metastatic breast cancer, lung cancer and advanced pancreatic cancer. Abraxane is the only drug of its kind to be approved in first line therapies across this broad spectrum of tumors in both the U.S. and E.U. Over the course of Dr. Soon-Shiong’s career, he has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has been granted over 230 patents worldwide for groundbreaking advancements spanning myriad fields of technology and medicine. As a surgeon, Dr. Soon-Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients.

In the early 1990’s, Dr. Soon-Shiong pursued the science of stem cell, microencapsulation and nanotechnology at NASA, performing experiments as part of the STS-95 Space Shuttle program. Soon-Shiong’s path to cancer research began while doing research for NASA that involved harnessing stem cells to make insulin. In 1991, he founded a biotechnology company to develop a novel nanoparticle anti-cancer drug with the concept of using “the tumors biology against itself”.

From 1997- 2010, Dr. Soon-Shiong served as Founder, Chairman and CEO of two global pharmaceutical companies: American Pharmaceutical Partners and Abraxis BioScience. In 2008, Dr. Soon-Shiong sold American Pharmaceutical Partners (NASDAQ: APP) to Fresenius for approximately $4.6 billion and in 2010, sold Abraxis Bio Science to Celgene for approximately $3.8 billion.

In January 2016, Dr. Soon-Shiong announced the formation of Cancer Breakthroughs 2020, a comprehensive collaboration of researchers, insurers, academic institutions and pharmaceutical companies that seeks to accelerate the potential of combination immunotherapy in the treatment of cancer. The initiative has a goal of initiating Phase 2 trials in 20,000 cancer patients within the next four years in addition to launching a revolutionary molecular diagnostic test. Known as GPS Cancer, the test enables analysis of the whole genome and target proteomics, transcending genomics to the era of clinic proteomics in cancer.

Dr. Soon-Shiong currently serves as Chairman and CEO of NantWorks, an ecosystem of companies aiming to create transformative global health information and next-generation pharma development network. Under the NantWorks umbrella, Soon-Shiong also currently serves as Chairman and CEO of NantKwest (NK), a Nasdaq listed immunotherapy company focusing on Natural Killer cells, and Chairman and CEO of NantHealth (NH), a Nasdaq listed transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system.

Dr. Soon-Shiong is Chairman of the Chan Soon-Shiong Family Foundation and of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. He co-chaired the CEO Council for Health and Innovation at the Bipartisan Policy Center, was the Executive Director of the UCLA Wireless Health Institute and a member of the Global Advisory Board of Bank of America. He also is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, and a Professor of Microbiology, Immunology & Molecular Genetics and Professor of Bioengineering at the California NanoSystems Institute of UCLA. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. In April 2016, Dr. Soon-Shiong received the Franklin Institute Award for his visionary leadership and commitment to advancing medical and scientific research and bringing new treatment options to cancer patients. Dr. Soon-Shiong was also honored at the Vatican in April 2016 and received the 2016 Pontifical Key Visionary Award. The award recognizes “medical innovators who change the course of history and reduce suffering on a global scale by blending visionary thinking with real action”. In June 2017, the Smithsonian Institute honored his work by placing Abraxane in the permanent exhibit at Smithsonian’s National Museum of American History.

Born and raised during apartheid in South Africa, Dr. Soon-Shiong resides in Los Angeles and is a citizen of the United States.

Patrick Soon-Shiong, MD, a physician, surgeon, researcher, philanthropist and scientist, invented and developed the revolutionary drug Abraxane, which has received FDA approval for the treatment of metastatic breast cancer, lung cancer and advanced pancreatic cancer. Abraxane is the only drug of its kind to be approved in first line therapies across this broad spectrum of tumors in both the U.S. and E.U. Over the course of Dr. Soon-Shiong’s career, he has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has been granted over 230 patents worldwide for groundbreaking advancements spanning myriad fields of technology and medicine. As a surgeon, Dr. Soon-Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients.

In the early 1990’s, Dr. Soon-Shiong pursued the science of stem cell, microencapsulation and nanotechnology at NASA, performing experiments as part of the STS-95 Space Shuttle program. Soon-Shiong’s path to cancer research began while doing research for NASA that involved harnessing stem cells to make insulin. In 1991, he founded a biotechnology company to develop a novel nanoparticle anti-cancer drug with the concept of using “the tumors biology against itself”.

From 1997- 2010, Dr. Soon-Shiong served as Founder, Chairman and CEO of two global pharmaceutical companies: American Pharmaceutical Partners and Abraxis BioScience. In 2008, Dr. Soon-Shiong sold American Pharmaceutical Partners (NASDAQ: APP) to Fresenius for approximately $4.6 billion and in 2010, sold Abraxis Bio Science to Celgene for approximately $3.8 billion.

In January 2016, Dr. Soon-Shiong announced the formation of Cancer Breakthroughs 2020, a comprehensive collaboration of researchers, insurers, academic institutions and pharmaceutical companies that seeks to accelerate the potential of combination immunotherapy in the treatment of cancer. The initiative has a goal of initiating Phase 2 trials in 20,000 cancer patients within the next four years in addition to launching a revolutionary molecular diagnostic test. Known as GPS Cancer, the test enables analysis of the whole genome and target proteomics, transcending genomics to the era of clinic proteomics in cancer.

Dr. Soon-Shiong currently serves as Chairman and CEO of NantWorks, an ecosystem of companies aiming to create transformative global health information and next-generation pharma development network. Under the NantWorks umbrella, Soon-Shiong also currently serves as Chairman and CEO of NantKwest (NK), a Nasdaq listed immunotherapy company focusing on Natural Killer cells, and Chairman and CEO of NantHealth (NH), a Nasdaq listed transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system.

Dr. Soon-Shiong is Chairman of the Chan Soon-Shiong Family Foundation and of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. He co-chaired the CEO Council for Health and Innovation at the Bipartisan Policy Center, was the Executive Director of the UCLA Wireless Health Institute and a member of the Global Advisory Board of Bank of America. He also is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, and a Professor of Microbiology, Immunology & Molecular Genetics and Professor of Bioengineering at the California NanoSystems Institute of UCLA. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. In April 2016, Dr. Soon-Shiong received the Franklin Institute Award for his visionary leadership and commitment to advancing medical and scientific research and bringing new treatment options to cancer patients. Dr. Soon-Shiong was also honored at the Vatican in April 2016 and received the 2016 Pontifical Key Visionary Award. The award recognizes “medical innovators who change the course of history and reduce suffering on a global scale by blending visionary thinking with real action”. In June 2017, the Smithsonian Institute honored his work by placing Abraxane in the permanent exhibit at Smithsonian’s National Museum of American History.

Born and raised during apartheid in South Africa, Dr. Soon-Shiong resides in Los Angeles and is a citizen of the United States.


Eleanor L. Ramirez RN, PHN, BSN, MS Chief Nursing OfficerEleanor L. Ramirez
RN, PHN, BSN, MS

Chief Nursing Officer

Ms. Eleanor Ramirez has extensive experience in the healthcare market, focusing on quality, operations, program management, infrastructure modeling and most clinical and support services. Ms. Ramirez was Chief Operating Officer of Saint John’s Health Center in Santa Monica, California responsible for overall operations of the Health Center.

Prior to her role at Saint John’s, Ms. Ramirez has served as Chief Operating Officer and as the Chief Nursing Officer for profit, non-profit health centers as well as independent and multi campus health centers.

Ms. Ramirez has served on numerous strategic operations and clinical technology committees for hospitals and large hospital systems. Ms. Ramirez has an undergraduate degree in Nursing and a graduate degree in Health Care Administration.

Ms. Eleanor Ramirez has extensive experience in the healthcare market, focusing on quality, operations, program management, infrastructure modeling and most clinical and support services. Ms. Ramirez was Chief Operating Officer of Saint John’s Health Center in Santa Monica, California responsible for overall operations of the Health Center.

Prior to her role at Saint John’s, Ms. Ramirez has served as Chief Operating Officer and as the Chief Nursing Officer for profit, non-profit health centers as well as independent and multi campus health centers. Ms. Ramirez has served on numerous strategic operations and clinical technology committees for hospitals and large hospital systems. Ms. Ramirez has an undergraduate degree in Nursing and a graduate degree in Health Care Administration.


Paula Bradshaw RN, MSN, MBA Clinic AdministratorPaula Bradshaw
RN, MSN, MBA

Clinic Administrator

Ms. Paula Bradshaw has 28 years’ experience in the healthcare arena. She trained and worked as a critical care nurse in the United Kingdom for 11 years. Paula joined the Nant family in 2016, and is currently the Administrator for the Chan Soon-Shiong Institute for Medicine Immuno-Oncology Network, Mariposa.

Paula came to the United States and joined Saint John’s Health Center, Santa Monica as an advanced practice nurse in 2001, where she established an end of life and pain management nursing program. In 2003, Paula was promoted to Director, Risk Management.

By 2006, Paula completed her MSN and MBA, and her responsibilities at Saint John’s expanded, she had responsibility for risk, and case management, healthcare quality, regulatory compliance, and John Wayne Cancer Centers. In 2010, she transitioned from the hospital to become Chief Nursing Officer at a software company, where she was responsible for software design and all client facing activity.

Ms. Paula Bradshaw has 28 years’ experience in the healthcare arena. She trained and worked as a critical care nurse in the United Kingdom for 11 years. Paula joined the Nant family in 2016, and is currently the Administrator for the Chan Soon-Shiong Institute for Medicine Immuno-Oncology Network, Mariposa.

Paula came to the United States and joined Saint John’s Health Center, Santa Monica as an advanced practice nurse in 2001, where she established an end of life and pain management nursing program. In 2003, Paula was promoted to Director, Risk Management. By 2006, Paula completed her MSN and MBA, and her responsibilities at Saint John’s expanded, she had responsibility for risk, and case management, healthcare quality, regulatory compliance, and John Wayne Cancer Centers. In 2010, she transitioned from the hospital to become Chief Nursing Officer at a software company, where she was responsible for software design and all client facing activity.

Conflict of Interest Policy

The Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, Mariposa (CSSIFM) acknowledges the importance of conflict of interest management which is why the Institute has proactively taken the appropriate steps and adopted a Conflict of Interest Policy (COI Policy) that requires comprehensive disclosure of the financial interests of Investigators conducting clinical research at the CSSIFM. See Conflict of Interest (COI) Policy which has been implemented in full prior to opening of the Institute.

For More Information

1-855-RxRxCSS

1-855-797-9277

Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, Mariposa
2040 East Mariposa Avenue
El Segundo, California 90245

We are not currently accepting walk-ins. Please call to schedule an appointment.